Login to Your Account

Clinic Roundup

Wednesday, May 18, 2011
Micromet Inc., of Bethesda, Md., published Phase II data showing that blinatumomab produced durable remissions in front-line acute lymphoblastic leukemia. While a 22 percent molecular response rate was expected, 80 percent of patients achieved a complete molecular response, all within the first cycle of treatment. Blinatumomab is an anti-CD19 antibody.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription